Ajinomoto Bio-Pharma Services Acquires Remaining Interest in Granules OmniChem Joint Venture in India

GeneDesign Joins Ajinomoto Bio-Pharma Services and Opens Oligonucleotide API Development Center

Jean-Baptiste Agnus Joins Ajinomoto Bio-Pharma Services’ Global Leadership Team as Vice President of Sales and Marketing

Ajinomoto Bio-Pharma Services Announces Capital Expansion to Fuel Growth

Ajinomoto and XL-protein forge Strategic Alliance to develop PASylated therapeutics applying the Corynex® platform

Ajinomoto Bio-Pharma Services Introduces AJICAP Bioconjugation Technology for ADC Manufacturing

Precision NanoSystems Announces Manufacturing Collaboration Agreement with Ajinomoto Bio-Pharma Services for GMP Manufacturing of High Quality Nanomedicines

Ajinomoto Althea and OmniChem Combine to Form Ajinomoto Bio-Pharma Services, Reflecting a Collective Range of Services Offered to the Bio-Pharma Industry

Ajinomoto Althea, Inc. Announces Additions to Management Team as it transforms into a global CDMO

The Government of Flanders recently agreed to participate in Ajinomoto OmniChem’s investments into new and innovative technologies.

On the 22nd September 2017 Granules OmniChem Limited (GOC) received the Establishment Inspection Report (EIR) from the US-FDA

Louvain-la-Neuve: New address from 01/10/2017

Ajinomoto Althea, Inc. Opens Manufacturing Suites in New High Potency and Antibody Drug Conjugate Commercial Facility

Ajinomoto Althea, Inc. Announces New Aseptic Fill Finish Line

CEO J. David Enloe Awarded 'Most Admired CEO'

Ajinomoto OmniChem Launches Flow Chemistry for API Commercial Manufacturing

Ajinomoto OmniChem Launches Flow Chemistry for API Commercial Manufacturing

Ajinomoto Group Acquires All Shares of GeneDesign, a Nucleic Acid Drug CDMO, to Accelerate Expansion of the Contract Business for Oligonucleotides.

Biologics candidate manufactured using Ajinomoto Co., Inc.’s CORYNEX® Protein Expression System enters clinical trials for the first time

Ajinomoto Althea, Inc. Announces Issuance of New US Patent for Manufacturing of Crystal Monoclonal Antibodies

Ajinomoto Althea, Inc. Expands Its Capacity of Fill Finish Manufacturing with Addition of Second Shift

Ajinomoto Althea, Inc. Launches Process and Analytical Development Services for Antibody Drug Conjugates (ADCs) Therapeutics

Ajinomoto Althea, Inc. Expands Manufacturing Capabilities to ADC Fill Finish and Bioconjugation

Ajinomoto Althea, Inc. Awarded CA Tax Credit

Ajinomoto Althea, Inc. Receives European GMP Certification for Commercial Aseptic Filling and Testing

Althea’s New Drug Formulation Technology Gains Attention from Two More Top Pharmaceutical Companies

Ajinomoto Althea, Inc. Receives European GMP Certification

Ajinomoto Althea Inc. Now Offering A Novel Protein Production Platform: Corynex®

Ajinomoto Althea Inc. Appoints J. David Enloe as President and Chief Executive Officer

Ajinomoto Althea, Inc. Selected as a Finalist in 26th Annual CONNECT Most Innovative New Product Awards

Ajinomoto Co., Inc. Completes Acquisition of Althea Technologies, Inc

Ajinomoto Co., Inc. Agrees to Acquire Althea Technologies, Inc.

Althea Technologies & Profectus Biosciences Sign Manufacturing Agreement for Plasmid DNA Production

Pfenex Inc. Awards Althea Technologies a Contract for cGMP Manufacturing of Circumsporozoite Protein from Plasmodium falciparum, a Key Malaria Antigen

Althea Technologies Announces Expanded Roles for Key Executives